Skip to Main Content

Federal officials on Wednesday alleged that Regeneron Pharmaceuticals (REGN) donated tens of millions of dollars to a foundation, but the payments were actually kickbacks to Medicare patients and designed to cover their out-of-pocket costs for a pricey eye medication.

In a lawsuit filed in federal court in Boston, the federal government accused Regeneron of using the Chronic Disease Fund to ensure that, in 2013 and 2014, Medicare patients did not have to make a co-payment or deductible for Eylea macular degeneration drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!